D. E. Shaw & Co. Inc. Purchases 248,871 Shares of Bausch Health Companies Inc. (NYSE:BHC)

D. E. Shaw & Co. Inc. boosted its stake in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 84.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 544,707 shares of the company's stock after purchasing an additional 248,871 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.15% of Bausch Health Companies worth $4,392,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its stake in Bausch Health Companies by 1,246.0% in the 4th quarter. JPMorgan Chase & Co. now owns 19,840 shares of the company's stock worth $160,000 after purchasing an additional 18,366 shares in the last quarter. SG Americas Securities LLC boosted its stake in Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock valued at $26,614,000 after buying an additional 1,263,706 shares during the period. Vanguard Group Inc. grew its position in Bausch Health Companies by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock worth $94,460,000 after buying an additional 145,078 shares in the last quarter. Raymond James Financial Inc. bought a new position in Bausch Health Companies in the 4th quarter worth about $180,000. Finally, Merit Financial Group LLC purchased a new stake in shares of Bausch Health Companies in the 4th quarter valued at about $228,000. 78.65% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. StockNews.com lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Finally, Royal Bank of Canada upped their price objective on Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat.com, Bausch Health Companies has a consensus rating of "Hold" and an average target price of $7.42.

Bausch Health Companies Stock Performance

BHC stock traded down $0.19 during trading on Wednesday, hitting $4.50. 1,164,810 shares of the company traded hands, compared to its average volume of 2,589,392. The company has a 50-day moving average of $5.46 and a 200-day moving average of $6.91. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $9.85. The firm has a market capitalization of $1.63 billion, a PE ratio of -37.46, a P/E/G ratio of 0.37 and a beta of 0.34.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The company had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Sell-side analysts expect that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.